Inmed announces appointment of interim chief financial officer and change of auditor

Vancouver, british columbia, dec. 12, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the company has entered into a service contract (the “contract”) with brio financial group (“brio”) to provide senior financial leadership and bookkeeping services. pursuant to the contract, mr. jonathan tegge, a member of brio, will assume the role of interim chief financial officer for the company effective december 12, 2022.
INM Ratings Summary
INM Quant Ranking